App-Quantinova.ai

A phase 1/2 study combining ipilimumab with abiraterone acetate plus prednisone in chemotherapy- and immunotherapy-naive patients with progressive metastatic castration resistant prostate cancer (mCRPC).

Daniel Costin Danila - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Prospective, non-interventional study on the influence of adherence measures on the therapy with abiraterone acetate (AA) + prednisone/prednisolone (P) in patients with metastatic, castration resistant prostate carcinoma.

Henrik Suttmann - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

CB-7598

A Phase II Study of the Dual mTOR Inhibitor MLN0128 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Dana E. Rathkopf - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Very-small-nuclear circulating tumor cell (vsnCTC) as a putative biomarker for visceral metastasis (VM) in metastatic castration-resistant prostate cancer (mCRPC).

Jie-Fu Chen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Benefit from next-generation ADT in AR-V7 positive patients.

Julie Steinestel - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Prospective evaluation of the cardiovascular safety profile of abiraterone acetate (AA) in mCRPC patients (pts).

Veronica Prati - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Cardiotoxicity

CB-7598

Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in chemotherapy-naive patients (CN-pts) with metastatic castration resistant prostate cancer (mCRPC).

Avivit Peer - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Patterns of metastatic disease progression after treatment with first-line enzalutamide or abiraterone in castration-resistant prostate cancer (CRPC).

Elizabeth K Lee - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Effect of abiraterone acetate (AA) and enzalutamide (EZ) administration on chemotherapy-naive metastatic castration-resistant prostate cancer (CN-mCRPC) patients symptom burden.

Sepehr Salem - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Multi-center assessment of stereotactic body radiotherapy in oligometastatic prostate cancer.

Steven E. Finkelstein - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

CB-7598

Open-label phase II study evaluating the efficacy of concurrent administration of radium Ra 223 dichloride and abiraterone acetate in men with castration-resistant prostate cancer patients with symptomatic bone metastases.

Luke T. Nordquist - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Intercalating docetaxel between novel hormone therapies (NHT) abiraterone and enzalutamide in metastatic castration resistant prostate cancer (mCRPC): Does it resensitize patients to the second NHT agent?

Benjamin Louis Maughan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Identifying candidates for prednisone to dexamethasone switch amongst patients with castration-resistant prostate cancer undergoing abiraterone therapy.

Vanessa Sarah Arciero - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Assessment of prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) after docetaxel (DOC).

Carla Cavaliere - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Influence of statins on survival outcomes in men with metastatic castration resistant prostate cancer treated with abiraterone.

Martin Boegemann - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Comorbid conditions in patients with castration-resistant prostate cancer (CRPC) receiving abiraterone.

Phoebe Cheng - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Circulating AR copy number and outcome to enzalutamide in patients with metastatic castration-resistant prostate cancer after docetaxel.

Samanta Salvi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Early prediction of therapy response to abiraterone acetate using PSA subforms in patients with castration resistant prostate cancer.

Katrin Schlack - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Association of CYP17A1 single nucleotide polymorphism (SNP) with response to abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).

Ben Yiming Zhang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Effect of radium 223 on remission of bone metastases in androgen receptor-positive (AR+) salivary duct carcinoma (SDC) of the parotid.

Mario Airoldi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Salivary gland cancer

CB-7598

Filters

959 Abstracts